13F filer · CIK 1479355
VHCP Management, LLC
NEW YORK, NY · filing since Q2 2013 · last filing Feb 13, 2017
Reported value
$93.0M
$-8.7M vs prior
Positions
21
New / sold out
1 / 4
Added / reduced
2 / 0
Turnover
4.7%
buys $4.6M · sells $5.4M
Top-10 weight
87.3%
Biggest buys vs Q3 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Ra Pharmaceuticals | +232,500 | – | +$3.5M |
| Added | BioCryst Pharmaceuticals Inc | +150,000 | +14.9% | +$949.5K |
| Added | Ocera Therapeutics | +55,500 | +6.5% | +$116.5K |
Biggest sells vs Q3 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Zafgen Inc | -602,114 | -100.0% | $-2.0M |
| Sold out | BeiGene Ltd | -51,000 | -100.0% | $-1.6M |
| Sold out | Achillion Pharmaceuticals Inc | -180,000 | -100.0% | $-1.5M |
| Sold out | REGENXBIO Inc | -24,089 | -100.0% | $-337.0K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q4 2016
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DBV TechnologiesCOM | 456,893 | $31.1M | 33.47% |
| 2 | Heron Therapeutics IncCOM | 1,095,734 | $14.4M | 15.43% |
| 3 | Coherus Biosciences IncCOM | 305,505 | $8.6M | 9.25% |
| 4 | BioCryst Pharmaceuticals IncCOM | 1,155,104 | $7.3M | 7.86% |
| 5 | Avadel PharmaceuticalsCOM | 500,000 | $5.2M | 5.59% |
| 6 | Ra PharmaceuticalsCOM | 232,500 | $3.5M | 3.80% |
| 7 | Adverum BiotechnologiesCOM | 1,102,735 | $3.2M | 3.44% |
| 8 | Lipocine IncCOM | 849,921 | $3.1M | 3.36% |
| 9 | CoLucid PharmaceuticalsCOM | 68,190 | $2.5M | 2.67% |
| 10 | Axovant Sciences LtdCOM | 184,110 | $2.3M | 2.46% |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.